Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alkion Bioinnovations is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by a distinct examiner within a distinct art unit, representing a focused prosecution profile. The company can concentrate its efforts on the specific patentability issues raised in this single active case.
The busiest examiner, JOHNSON, EMILY KATHARINE, is responsible for the 1 pending office action. Because this examiner is the only official currently reviewing the company's pending work, their specific feedback is the most important factor in the portfolio's immediate future. The lack of examiner or art unit diversity means the company's current success depends entirely on the resolution of this action.
Operating within a single art unit provides a clear administrative path for the applicant, as they only need to comply with one set of unit-specific guidelines. Practitioners should focus on the preferences and previous actions of JOHNSON, EMILY KATHARINE to develop an effective response. This targeted strategy is efficient for managing the sole pending action currently active in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, EMILY KATHARINE | 1 | 87.5% | +21.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847912 | BIOLOGICAL METHOD FOR DECARBOXYLATION OF CANNABINOIDS DIRECTLY IN PLANT TISSUES | JOHNSON, EMILY KATHARINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847912 | BIOLOGICAL METHOD FOR DECARBOXYLATION OF CANNABINOIDS DIRECTLY IN PLANT TISSUES | JOHNSON, EMILY KATHARINE | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847912 | BIOLOGICAL METHOD FOR DECARBOXYLATION OF CANNABINOIDS DIRECTLY IN PLANT TISSUES | JOHNSON, EMILY KATHARINE | 1662 | §103§112 | Non-Final OA | — | Pending | Sep 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlkion Bioinnovations has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emily Katharine Johnson has the most, with 1 of Alkion Bioinnovations's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
